The Ludwig Institute for Cancer Research Melbourne Melanoma Cell Line Panel

作者：Andreas Behren, Matthew Anaka, Pu‐Han Lo, Laura J. Vella, Ian D. Davis, Jenny Catimel, Tracy Cardwell, Craig Gedye, Christopher Hudson, Rodica Stan, Jonathan Cebon · 发表于：Pigment Cell & Melanoma Research · 年份：2013 · DOI：10.1111/pcmr.12097 · 被引用次数：57 · 研究领域：Immunotherapy and Immune Responses、vaccines and immunoinformatics approaches、CAR-T cell therapy research

We established a range of melanoma cell lines from patient material (Table 1) termed Ludwig-Melbourne-Melanoma (LM-MEL-) followed by a unique number (method: Anaka et al., 2012). These lines have been human leucocyte antigen (HLA)-typed, their mutational status for common mutated genes in melanoma determined using the Sequenom MelCarta panel, and their transcriptomes profiled. All lines are tested for mycoplasma, and ethical approval for research purposes has been granted by the Austin Health Human Research Ethics Committee (HREC). Therapeutic options for advanced stage melanoma are limited, and despite the recent success with inhibitors of mutant v-raf murine sarcoma viral oncogene homolog B1 (BRAF) activity, long-lasting responses remain rare (Chapman et al., 2011). Immunotherapy may help overcome treatment failure, and there has been some success in the clinic with immunotherapy agents (Hodi et al., 2010). Knowledge of the antigen presenting major histocompatibility complex (MHC) class I HLA-types and antigenic proteins expressed by model systems is crucial for the preclinical testing of immunological interventions such as therapeutic cancer vaccines. Cancer-testis antigens (CTAg) and differentiation-antigens [mainly regulated by the microphtalmia-associated transcription factor (MITF)], represent two of the most studied families of potential cancer vaccine targets in melanoma (Caballero and Chen, 2009); and show various degrees of tissue-restriction and immunogenicity. Th...